{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016108","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.142578+00:00","generated_at":"2026-05-29T05:12:18.057238+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NextCure FDA accepts IND for ADC LNCB74; Phase 1 trial to start","bullets":["FDA accepted IND for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC).","Phase 1 trial will evaluate LNCB74 for multiple cancers.","LNCB74 developed in partnership with LigaChem Biosciences under co-development agreement.","NextCure CEO Michael Richman highlighted differentiation from other B7-H4 ADCs.","IND acceptance allows NextCure to proceed with clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016108","json":"https://secwatch.observer/filing/0001558370-24-016108.json","markdown":"https://secwatch.observer/filing/0001558370-24-016108.md","text":"https://secwatch.observer/filing/0001558370-24-016108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024016108/0001558370-24-016108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024016108/nxtc-20241210x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:12:18.057238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}